Reuters logo
2 years ago
Amgen's bone drug succeeds in late-stage study
September 1, 2015 / 8:52 PM / 2 years ago

Amgen's bone drug succeeds in late-stage study

Sept 1 (Reuters) - Amgen Inc said its experimental bone drug was found to be more effective than an already marketed drug in a late-stage study.

Amgen's drug, romosozumab, met the main goal of showing a significant difference over teriparatide in improving total hip bone density by the 12th month in postmenopausal women with osteoporosis.

Osteoporosis is a condition which causes bones to become weak and brittle leading to an increased risk of fracture. (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below